Clovis Oncology (CLVS) to Release Quarterly Earnings on Monday

Clovis Oncology (NASDAQ:CLVSGet Rating) is set to post its quarterly earnings results before the market opens on Monday, August 8th. Analysts expect Clovis Oncology to post earnings of ($0.41) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Clovis Oncology (NASDAQ:CLVSGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The company had revenue of $34.25 million for the quarter, compared to analysts’ expectations of $37.03 million. During the same quarter last year, the firm posted ($0.64) earnings per share. On average, analysts expect Clovis Oncology to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clovis Oncology Trading Up 1.2 %

Shares of NASDAQ CLVS opened at $1.66 on Friday. The stock has a market cap of $238.84 million, a price-to-earnings ratio of -0.79 and a beta of 0.45. Clovis Oncology has a 52 week low of $0.58 and a 52 week high of $5.06. The company’s 50-day moving average price is $1.60 and its 200 day moving average price is $1.70.

Institutional Trading of Clovis Oncology

Hedge funds have recently made changes to their positions in the stock. Mirabella Financial Services LLP acquired a new position in Clovis Oncology in the first quarter worth $36,000. First Republic Investment Management Inc. bought a new stake in shares of Clovis Oncology during the first quarter valued at about $27,000. Wellington Management Group LLP raised its position in Clovis Oncology by 7.5% in the first quarter. Wellington Management Group LLP now owns 466,652 shares of the biopharmaceutical company’s stock worth $942,000 after acquiring an additional 32,669 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Clovis Oncology in the first quarter worth about $132,000. Finally, Renaissance Technologies LLC raised its position in Clovis Oncology by 139.2% in the first quarter. Renaissance Technologies LLC now owns 1,459,900 shares of the biopharmaceutical company’s stock worth $2,949,000 after acquiring an additional 849,500 shares in the last quarter. Institutional investors and hedge funds own 36.64% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright lowered shares of Clovis Oncology from a “buy” rating to a “neutral” rating in a report on Friday, May 6th.

About Clovis Oncology

(Get Rating)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Stories

Earnings History for Clovis Oncology (NASDAQ:CLVS)

Want More Great Investing Ideas?

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.